MAPT and Alzheimer disease: Jiang et al., showed that miR-23b-3p targets glycogen synthase kinase-3β (GSK-3β) to prevent tau hyperphosphorylation in vitro as well as in an AD mouse model (APP/PS1 mice) [100].